NexImmune Competitors

NexImmune (NASDAQ:NEXI) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for NexImmune and BioAtla, as provided by MarketBeat.

NexImmune currently has a consensus price target of $33.3333, indicating a potential upside of 78.54%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 23.72%. Given NexImmune's higher probable upside, equities research analysts plainly believe NexImmune is more favorable than BioAtla.

Profitability

This table compares NexImmune and BioAtla's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares NexImmune and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

Cullinan Oncology (NASDAQ:CGEM) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Cullinan Oncology and NexImmune's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cullinan Oncology and NexImmune, as provided by MarketBeat.com.

Cullinan Oncology currently has a consensus price target of $48.75, indicating a potential upside of 51.16%. NexImmune has a consensus price target of $33.3333, indicating a potential upside of 78.54%. Given NexImmune's stronger consensus rating and higher probable upside, analysts clearly believe NexImmune is more favorable than Cullinan Oncology.

Earnings & Valuation

This table compares Cullinan Oncology and NexImmune's top-line revenue, earnings per share (EPS) and valuation.

Summary

NexImmune beats Cullinan Oncology on 2 of the 2 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Valuation and Earnings

This table compares Silverback Therapeutics and NexImmune's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Silverback Therapeutics and NexImmune's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings for Silverback Therapeutics and NexImmune, as reported by MarketBeat.

Silverback Therapeutics presently has a consensus target price of $50.25, indicating a potential upside of 40.72%. NexImmune has a consensus target price of $33.3333, indicating a potential upside of 78.54%. Given NexImmune's higher probable upside, analysts plainly believe NexImmune is more favorable than Silverback Therapeutics.

NexImmune (NASDAQ:NEXI) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares NexImmune and Nurix Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for NexImmune and Nurix Therapeutics, as reported by MarketBeat.

NexImmune presently has a consensus target price of $33.3333, suggesting a potential upside of 78.54%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 64.44%. Given NexImmune's higher probable upside, equities analysts clearly believe NexImmune is more favorable than Nurix Therapeutics.

Earnings and Valuation

This table compares NexImmune and Nurix Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Insider and Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nurix Therapeutics beats NexImmune on 2 of the 3 factors compared between the two stocks.

Cricut (NASDAQ:EWTX) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Valuation & Earnings

This table compares Cricut and NexImmune's revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cricut and NexImmune, as provided by MarketBeat.com.

NexImmune has a consensus price target of $33.3333, suggesting a potential upside of 78.54%. Given NexImmune's stronger consensus rating and higher possible upside, analysts plainly believe NexImmune is more favorable than Cricut.

Profitability

This table compares Cricut and NexImmune's net margins, return on equity and return on assets.

Summary

NexImmune beats Cricut on 2 of the 2 factors compared between the two stocks.

NexImmune (NASDAQ:NEXI) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Profitability

This table compares NexImmune and Kinnate Biopharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares NexImmune and Kinnate Biopharma's revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent ratings for NexImmune and Kinnate Biopharma, as provided by MarketBeat.

NexImmune presently has a consensus price target of $33.3333, suggesting a potential upside of 78.54%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 92.81%. Given Kinnate Biopharma's higher possible upside, analysts clearly believe Kinnate Biopharma is more favorable than NexImmune.

Summary

Kinnate Biopharma beats NexImmune on 2 of the 2 factors compared between the two stocks.